AbbVieABBV
ABBV
About: AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Employees: 50,000
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
197% more first-time investments, than exits
New positions opened: 389 | Existing positions closed: 131
5% more funds holding
Funds holding: 3,448 [Q3] → 3,630 (+182) [Q4]
1.68% more ownership
Funds ownership: 70.35% [Q3] → 72.03% (+1.68%) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 1,478 | Existing positions reduced: 1,381
6% more call options, than puts
Call options by funds: $3.18B | Put options by funds: $2.99B
5% less capital invested
Capital invested by funds: $246B [Q3] → $233B (-$12.4B) [Q4]
20% less funds holding in top 10
Funds holding in top 10: 207 [Q3] → 165 (-42) [Q4]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$190
9%
upside
Avg. target
$217
24%
upside
High target
$241
38%
upside
10 analyst ratings
7 positive
70%
3 neutral
30%
0 negative
0%
Morgan Stanley Terence Flynn 33% 1-year accuracy 7 / 21 met price target | 38%upside $241 | Overweight Maintained | 9 Apr 2025 |
Goldman Sachs Asad Haider 50% 1-year accuracy 1 / 2 met price target | 11%upside $194 | Neutral Assumed | 8 Apr 2025 |
Wells Fargo Mohit Bansal 15% 1-year accuracy 4 / 27 met price target | 37%upside $240 | Overweight Maintained | 5 Mar 2025 |
B of A Securities Tim Anderson 43% 1-year accuracy 6 / 14 met price target | 27%upside $223 | Neutral Maintained | 4 Mar 2025 |
Citigroup Geoff Meacham 23% 1-year accuracy 8 / 35 met price target | 23%upside $215 | Buy Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 59 articles about ABBV published over the past 30 days
Neutral
CNBC Television
18 hours ago
Final Trades: TJX, Meta, Abbvie and Taiwan Semi
The Investment Committee give you their top stocks to watch for the second half.
Neutral
Accesswire
18 hours ago
Shareholders of Cerevel Therapeutics Holdings, Inc. Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - ABBV
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Cerevel Therapeutics Holdings, Inc. (NYSE:ABBV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cerevel-therapeutics-holdings-inc-lawsuit-submission-form?prid=142536&wire=1 or contact Joseph E. Levi, Esq.
Negative
CNBC
21 hours ago
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Positive
Zacks Investment Research
1 day ago
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Neutral
Zacks Investment Research
1 day ago
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Positive
Benzinga
2 days ago
AbbVie Stock Up 9.2% After Key Signal
ALERT COMES AT LOW POINT FOR ABBV AND SIGNALS MAJOR REVERSAL OF OVER 15 POINTS
Positive
CNBC
2 days ago
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing a "lack of respect.
Neutral
CNBC Television
2 days ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Positive
Seeking Alpha
2 days ago
AbbVie: Thriving Beyond Humira's Patent Cliff (Upgrade)
AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% year-over-year, projecting combined revenue exceeding $31 billion by 2027. Despite Imbruvica's 7% decline, the oncology portfolio grew 11% through Venclexta and Elahere's strong performance.
Negative
Seeking Alpha
2 days ago
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.
Charts implemented using Lightweight Charts™